Published in Journal of Alzheimer's disease : JAD
Alzheimer's disease (AD) is the most common type of dementia, causing progressive decline of memory, thinking, and behavior, impairing daily functioning. Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia. The aim of this study was to investigate symptomatic treatment prevalence and treatment patterns in eAD. Emb...
Published in Journal of Alzheimer's disease : JAD
The concept of mild cognitive impairment (MCI) has evolved since its original conception. So, too, have MCI diagnostic methods, all of which have varying degrees of success in identifying individuals at risk of conversion to dementia. The neuropsychological actuarial method is a straightforward diagnostic approach that has shown promise in large da...
Published in Journal of Alzheimer's disease : JAD
The CERAD Word List Memory Test (WLMT) is widely used in the assessment of older adults with suspected dementia. Although normative data of the WLMT exist in many different regions of the world, normative data based on large population-based cohorts from the Scandinavian countries are lacking. To develop normative data for the WLMT based on a large...
Published in Journal of Alzheimer's disease : JAD
The uncompetitive NMDA antagonist, memantine (MEM), enhances prepulse inhibition of startle (PPI) across species. MEM is used to treat Alzheimer's disease (AD); conceivably, its acute impact on PPI might be used to predict a patient's sensitivity to MEM's therapeutic effects. To begin to test this possibility, we studied MEM effects on PPI and rela...
Published in Journal of Alzheimer's disease : JAD
Possin and Rosen provide a robust commentary exploring the challenges of using caregivers as cognitive testers. Informants have an important and often overlooked role in diagnosing cognitive impairment. O'Caoimh et al. show they can support cognitive screening in advance of clinic, suggesting new research avenues including the potential for home-mo...
Published in Journal of Alzheimer's disease : JAD
The proportion of people living with dementia in low- and middle-income countries (LMICs) is expected to reach 71% by 2050. Appraising the economic burden of the disease may contribute to strategic policy planning. To review studies conducted on the costs of dementia in LMICs, describe their methodology and summarize available costs estimates. Syst...
Published in Journal of Alzheimer's disease : JAD
Published in Journal of Alzheimer's disease : JAD
The 14-3-3 protein in cerebrospinal fluid (CSF) is a suitable biomarker for the diagnosis of Creutzfeldt-Jakob disease (CJD). However, it has also been detected in various non-prion-related rapidly progressive dementia (RPD), which affected its diagnostic performance and clinical utilization. To investigate the general disease distribution with pos...
Published in Journal of Alzheimer's disease : JAD
Establishing preventive measures to improve cognitive health of the growing older adult population is a public health priority. Though, the links between low-cost non-pharmacologist interventions that target activities like hobbies and cognitive health remain unclear. We conducted a topical review of extant literature to characterize prior findings...
Published in Journal of Alzheimer's disease : JAD
Age at onset was suggested as one possible risk factor for motor dysfunction in Alzheimer's disease (AD). We investigated the association of motor symptoms with cognition or neurodegeneration in patients with AD, and whether this association differs by the age at onset. We included 113 amyloid positive AD patients and divided them into early-onset ...
